Evidence map›Paper›PMID 41246467›Full record

ArticleIJTLD open2025

Development and evaluation of the phenotypic 2G test to detect drug-resistant TB.

J I Garcia, E T Mambuque, A D Hicks, A Schami, S Munguambe, N Gomez, G Tembe, B Saavedra, S-H Wang, J-M Balada-Llasat and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJTLD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

J I GarciaInternational Center for the Advancement of Research and Education (I•CARE), Texas Biomedical Research Institute, San Antonio, TX, USA.
E T MambuqueCentro de Investigação em Saúde de Manhiça (CISM), Maniça, Mozambique.
A D HicksInternational Center for the Advancement of Research and Education (I•CARE), Texas Biomedical Research Institute, San Antonio, TX, USA.
A SchamiInternational Center for the Advancement of Research and Education (I•CARE), Texas Biomedical Research Institute, San Antonio, TX, USA.
S MunguambeCentro de Investigação em Saúde de Manhiça (CISM), Maniça, Mozambique.
N GomezCentro de Investigação em Saúde de Manhiça (CISM), Maniça, Mozambique.
G TembeCentro de Investigação em Saúde de Manhiça (CISM), Maniça, Mozambique.
B SaavedraCentro de Investigação em Saúde de Manhiça (CISM), Maniça, Mozambique.
S-H WangDivision of Infectious Diseases, Department of Internal Medicine, The Ohio State University, Global One Health initiative (GOHi), College of Medicine, Columbus, OH, USA.
J-M Balada-LlasatDepartment of Pathology, College of Medicine, The Ohio State University, Columbus, OH, USA.
B I RestrepoSchool of Public Health, University of Texas Health Science Center at Houston, Brownsville, TX, USA.
M YotebiengDivision of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine, The Bronx, NY, USA.
J GelfondDepartment of Population Health Sciences, UT Health San Antonio, San Antonio, TX, USA.
A L Garcia-BasteiroCentro de Investigação em Saúde de Manhiça (CISM), Maniça, Mozambique.
J B TorrellesInternational Center for the Advancement of Research and Education (I•CARE), Texas Biomedical Research Institute, San Antonio, TX, USA.

Funding

Interdisciplinary NexGen TB research Advancement Center (IN-TRAC)P30AI168439 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI JOANNE TURNER · 2022 to 2026
$6.9M
Improving rapid phenotypic drug susceptibility testing for drug resistant tuberculosis in high-burden areasR01AI176309 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI BLANCA I RESTREPO, Jordi B Torrelles · 2023 to 2026
$3.5M
NIAID NIH HHS P30 AI168439NIAID NIH HHS R01 AI176309
6 · The paper itself

Abstract

backgroundEarly diagnosis of TB with drug susceptibility testing (DST) is critical to achieve successful treatment outcomes. We aimed to develop and test a novel colorimetric, 12-well, thin-layer agar-based test to assess its accuracy for TB diagnosis and DST in a clinical setting in Southern Mozambique.

methodsDevelopment of the first prototype of the second generation (2G) test in the laboratory setting followed by a cross-sectional diagnostic accuracy study with consecutive recruitment of subjects with microbiologically confirmed TB using GeneXpert MTB/RIF Ultra.

resultsIn the laboratory setting, the 2G test showed 100% accuracy in detecting resistance of genotypically characterised drug-resistant

conclusionIn the clinical setting, the 2G test showed a low sensitivity versus Xpert and MGIT. The 2G test sensitivity was lower when frozen instead of fresh sputa was used. Despite these results, important information was collected to further improve this 2G test prototype and its implementation in resource-constrained settings.

Indexed as

DR-TBdrug susceptibility testingMozambiqueMycobacterium tuberculosisthin-layer culturetuberculosis

Identifiers

PMID41246467
PMCPMC12617084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.